The Consortium (Clinical Endocannabinoid System Consortium, CESC)

What The Consortium (Clinical Endocannabinoid System Consortium, CESC) does

The Consortium (Clinical Endocannabinoid System Consortium, CESC) is a San Francisco-based nonprofit founded in 2015 that operates across medicinal cannabis therapeutics, organized into four integrated pillars: Research, Community, Education, and Regulatory Affairs. Its research programs include the Dosing Project (safe and effective product guidelines), Cannabis Mind (neuropsychiatric studies with EEG), Women's Health (long-term wellness research), and peer-reviewed research initiatives. The organization has stated it has accumulated 500,000 cannabis patient consultations and 60 combined years of drug development and clinical observation experience across its team, with a research community of more than 7,000 patients willing to participate in studies.

The company's core technology is not explicitly disclosed in available source material; its value lies in its research datasets, peer-reviewed outputs, and community of patients, legacy growers, dispensary owners, and medical professionals. It sustains a go-to-market built on community engagement, weekly research discussions, conference speaking engagements, and an educational platform called Cannabis Public School that delivers curriculum on cannabis biology, medical benefits, and historical use. The organization also engages in regulatory advisory and lobbying for cannabis quality standards.

Commercially, The Consortium operates as a nonprofit with approximately 5 employees, classified under a professional services revenue model. Pricing is not publicly disclosed, and no specific revenue or funding figures are available. Its customer base spans patients seeking cannabis therapy, healthcare providers and operators seeking certification, women's health professionals and communities, and regulators, foundations, and brands seeking research-grade evidence on cannabis products. The organization maintains ten strategic partnerships spanning cultivation, formulation, product manufacturing, education, and consulting.

Name

The Consortium (Clinical Endocannabinoid System Consortium, CESC)

Legal name

The Consortium

Website

https://theconsortium.io

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

The Consortium (CESC) is a San Francisco-based nonprofit that generates real-world evidence on cannabis therapeutics and delivers education to patients, healthcare providers, and communities, organized across research, community, education, and regulatory affairs pillars.

Ownership category

akta.pro rank

Headquarters

HQ city

San Francisco, California (CA)

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Nonprofit Operations: The Consortium is described as a nonprofit organization generating real-world evidence (RWE) on cannabis products while delivering education to the community. Specific revenue generation mechanisms are not disclosed in the available source material.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

The Consortium is a nonprofit organization that generates real-world evidence (RWE) on the safety and effectiveness of cannabis products and delivers cannabis and wellness education to the community. It operates four integrated service pillars: Research Programs (Dosing Project, Cannabis Mind, Women's Health, Peer Reviewed Research), Community Programs (patient outreach, weekly research discussions, speaking engagements), Education Programs (Cannabis Public School, instructional materials, specialist certification), and Regulatory Affairs Services (agency collaboration, regulatory framework advisory, lobbying).

Product overview

The Consortium is a nonprofit organization offering a unified platform focused on research, community, and education in the medicinal cannabis therapeutics space. The organization operates through four integrated pillars: Research Programs (Dosing Project, Cannabis Mind, Women's Health, Peer Reviewed Research), Community Programs (patient outreach, weekly research discussions, speaking engagements, community engagements), Education Programs (Cannabis Public School, instructional materials, specialist certification), and Regulatory Affairs Services (agency collaboration, regulatory advisory, lobbying). These programs work together to bridge the void between science and community by providing trusted, real-world evidence of product safety and effectiveness while delivering education to the community related to cannabis and wellness.

Differentiator

Problem solved

Functional benefit

Products and services

• Research Programs

Quantifiable outcome

• 500k+ cannabis patient consultations completed
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core and minor.

• VertosacoreTechnology or IntegrationVertosa is a manufacturer of emulsified beverage formulations. The partnership supports the Consortium's research into cannabis product safety and effectiveness by providing expertise in formulation science.
• The Bohemian ChemistcoreStrategic or Co-development PartnerCannabis cultivator of rare cultivars. Partnership focuses on cultivation research and product development collaboration for therapeutic applications.
• Leading CannabisminorImplementation/ SI/ Consulting PartnerLeading Cannabis business consultants provide industry expertise and strategic guidance to support the Consortium's research and education initiatives.
• Moon Made FarmscoreStrategic or Co-development PartnerWoman owned Cannabis Cultivator focused on sustainable and ethical cannabis production. Partnership supports women's health research initiatives.
• Hello Again ProductscoreStrategic or Co-development PartnerCannabis manufacturer focused on women's health. Partnership aligns with Consortium's Women's Health research program for long-term wellness studies.
• Arcanna FlowersminorStrategic or Co-development PartnerLegacy Cultivator and Community Cultivation organization. Partnership supports community engagement and cultivation research.
• Cannabis Public SchoolcoreGTM or Marketing PartnerEducational initiative educating the cannabis community on the endocannabinoid system. Close alignment with Consortium's education pillar and mission.
• Flore DispensaryminorChannel Partner/ Reseller/ DistributorLegacy Cannabis operator and community activist organization. Partnership supports community outreach and patient access to therapeutic cannabis.
• SnowtillminorStrategic or Co-development PartnerZero waste Cannabis cultivation operation. Partnership supports sustainable cannabis research and environmentally responsible cultivation practices.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Cannabis Public School: Cannabis Public School is an education platform founded by Consortium team member Mo Smyth to teach the public about cannabis biology and the endocannabinoid system. It is closely tied to The Consortium and represents a direct channel partner for the Consortium's education pillar.
• Patients Out of Time: Patients Out of Time is a nonprofit focused on educating healthcare professionals and the public about medical cannabis through accredited conferences and continuing education. It overlaps with The Consortium's education pillar, particularly around specialist certification and practitioner training.
• American Cannabis Nurses Association: The American Cannabis Nurses Association is a professional nursing organization advancing cannabis nursing practice through education and advocacy. It is comparable to The Consortium's practitioner education and certification work, though narrower in clinical scope to nursing.

Direct peers

• Marijuana Policy Project: Marijuana Policy Project is a major cannabis policy nonprofit focused on legislative reform, lobbying, and public education. It shares The Consortium's regulatory affairs and community-stigma-reduction missions, but operates at a larger national scale on policy rather than clinical research.
• Society of Cannabis Clinicians: The Society of Cannabis Clinicians is a nonprofit professional association of physicians and healthcare professionals focused on cannabis therapeutics research and education. It is the most direct peer to The Consortium, sharing a medical-research, education, and clinical community-building mission in medicinal cannabis.
• Realm of Caring: Realm of Caring is a nonprofit that provides cannabinoid therapy education, patient support, and observational research in partnership with academic institutions. It is directly comparable to The Consortium's community-research-education model, with similar patient-outreach and RWE-orientation toward medical cannabis.
• Americans for Safe Access: Americans for Safe Access is a nonprofit that advocates for medical cannabis patient access, develops policy frameworks, and produces educational resources for patients and providers. It overlaps with The Consortium on regulatory advocacy, patient outreach, and standards-setting for the medical cannabis community.
• NORML: NORML is a nonprofit cannabis policy reform organization that engages in advocacy, public education, and community organizing around cannabis legalization and patient rights. It is comparable to The Consortium's community-engagement and regulatory-advocacy functions, though NORML is broader (recreational) and less focused on clinical RWE generation.

Broad incumbents

• Drug Policy Alliance: Drug Policy Alliance is a large nonprofit that advocates for drug policy reform across substances, including cannabis. It overlaps with The Consortium's regulatory advocacy and stigma-reduction work but is broader in scope (all controlled substances) and operates at a national policy level.

Others

• Healium XR: Healium XR is a neuroscience-based wellness technology company where Consortium Scientific Advisor Dr. Jeff Tarrant serves as Chief Science Officer. It is an adjacent ecosystem partner sharing the Consortium's brain-health and EEG research interests rather than a direct competitor.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/the-clinical-endocannabinoid-system-consortium-cesc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Consortium (Clinical Endocannabinoid System Consortium, CESC)